Loading clinical trials...
Loading clinical trials...
A Multicentre Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) Co-administered With Boostrix Polio (dTpa-IPV) in Healthy Female Subjects Aged 10-18 Years
Conditions
Interventions
Boostrix ® Polio
GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)
Locations
38
France
GSK Investigational Site
Auch, France
GSK Investigational Site
Draguignan, France
GSK Investigational Site
Essey-lès-Nancy, France
GSK Investigational Site
Évreux, France
GSK Investigational Site
Le Havre, France
GSK Investigational Site
Luynes, France
Start Date
February 13, 2007
Primary Completion Date
March 17, 2008
Completion Date
July 25, 2008
Last Updated
July 20, 2018
NCT01627561
NCT00196937
NCT01462357
NCT01190176
NCT01277042
NCT00345878
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions